Literature DB >> 10479496

Expression and imprinting of insulin-like growth factor II (IGF2) and H19 genes in uterine leiomyomas.

C A Rainho1, A Pontes, S R Rogatto.   

Abstract

Genomic imprinting is defined as a gamete of origin-specific epigenetic modification of DNA leading to differential gene expression in the zygote. Several imprinted genes have been identified and some of them are associated with tumor development. We investigated the expression and the imprinting status of IGF2 and H19 genes in 47 uterine leiomyomas. Using allelic transcription assay, we detected the expression of the IGF2 gene in 10 of a total of 15 informative cases. No loss of imprinting, as determined by the finding of biallelic expression, was detected in any case. The expression of H19 gene was detected in 10 of 20 informative cases and the imprinting pattern was also maintained in all of them. Our data suggest that alterations in IGF2 and H19 genes expression by loss of imprinting do not occur in uterine leiomyomas. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10479496     DOI: 10.1006/gyno.1999.5483

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  3 in total

1.  Insights from gene arrays on the development and growth regulation of uterine leiomyomata.

Authors:  John C M Tsibris; James Segars; Domenico Coppola; Shrikant Mane; George D Wilbanks; William F O'Brien; William N Spellacy
Journal:  Fertil Steril       Date:  2002-07       Impact factor: 7.329

2.  Analyzing large gene expression and methylation data profiles using StatBicRM: statistical biclustering-based rule mining.

Authors:  Ujjwal Maulik; Saurav Mallik; Anirban Mukhopadhyay; Sanghamitra Bandyopadhyay
Journal:  PLoS One       Date:  2015-04-01       Impact factor: 3.240

Review 3.  Long Non-coding RNAs Involved in Resistance to Chemotherapy in Ovarian Cancer.

Authors:  Cecilie Abildgaard; Luisa M Do Canto; Karina D Steffensen; Silvia R Rogatto
Journal:  Front Oncol       Date:  2020-01-21       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.